Clinical Trials Logo
  1. Home
  2. Non-hodgkin Lymphoma,B Cell
  3. NCT05741359

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma,B Cell Clinical Trial

Official title:
A Phase I/II Clinical Study of the Safety and Efficacy of CD19-targeted Non-viral PD1 Site-specific Integrated CAR-T Cell Injection (BRL-201) in the Treatment of Relapsed or Refractory B Lymphocyte Non-Hodgkin Lymphoma

Clinical Trial Summary

This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.

Clinical Trial Description

This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects. Based on the "3 + 3" dose escalation design principle, subjects will be divided into 3 groups from low dose to high dose in sequence (Group A; Group B; Group C. Additional subjects will be enrolled into the RP2D group to ensure that 6-9 efficacy-evaluable subjects are available in the RP2D group before entering the phase II study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05741359
Study type Interventional
Source Bioray Laboratories
Contact Wei Li, PhD
Phone 18621670308
Email wli@brlmed.com
Status Recruiting
Phase Phase 1
Start date April 25, 2023
Completion date March 15, 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05050461 - Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma N/A
Recruiting NCT06160362 - The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) N/A
Recruiting NCT04435743 - Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas
Recruiting NCT03720496 - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy Phase 1
Recruiting NCT05518383 - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Phase 4
Recruiting NCT02081937 - CART-19 Immunotherapy in Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT06321289 - Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Not yet recruiting NCT05909059 - CAR T-cell Therapy in Patients With Renal Dysfunction Phase 2
Recruiting NCT05631912 - TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Completed NCT04094142 - Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Phase 2
Not yet recruiting NCT06156774 - SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
Recruiting NCT05143112 - Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT04661020 - CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT03497533 - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 Phase 1/Phase 2
Recruiting NCT04532268 - A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL Early Phase 1
Terminated NCT03488251 - PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT04897477 - Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Not yet recruiting NCT06346912 - CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL Early Phase 1